One in eight U.S. adults uses GLP-1 drugs; Medicare now opens weight-loss access

Key Points:

• The GLP-1 Bridge Program, starting July 1, 2026, allows Medicare Part D beneficiaries to access GLP-1 weight-loss drugs like Wegovy and Foundayo for the first time, outside of standard Part D coverage.
• The pilot program runs through December 31, 2027, is centrally managed by Medicare, and requires prior authorization from a healthcare provider confirming eligibility based on BMI and health conditions.
• Eligible beneficiaries pay a flat $50 copay for covered GLP-1 drugs, but this cost does not count toward their Part D deductible or out-of-pocket catastrophic limit.
• The program covers all formulations of Wegovy and Foundayo, plus the KwikPen formulation of Zepbound, and is available nationwide, including all U.S. territories.
• GLP-1 drugs can result in significant weight loss (14–20% of body weight in a year) but must be taken continuously to maintain results, as stopping the medication often leads to regaining weight; side effects may cause some to discontinue use.